PRECISE PHARMACOGENOMICS (PGx)
Book An Appointment Today
Personalize your medication, minimize side effects, and optimize treatment with
PRECISE Pharmacogenomics.
Only at Precision Diagnostics
Dr. Doreen Tan Su-Yin
Associate Professor
Board Advisor, Precision Diagnostics
Principal Investigator, Pharmacogenomics Implementation – A Precision Medicine Initiative
International Society of Cardiovascular Pharmacotherapy (ISCP) - President Elect
Pharmaceutical Society of Singapore (PSS) - Vice President
Pharm. D., BSc (Pharm)
Doctor Doreen Tan is a cardiology specialist pharmacist at the National University Heart Centre, Singapore, and Associate Professor with NUS Department of Pharmacy and Pharmaceutical Sciences. She is a leading advocate for precision medicine and pharmacogenomics in cardiovascular care.
She works closely with Dr. Rebecca Tay, CEO of Global Precision Diagnostics, as one of the Principal Investigators for the Implementation of Pharmacogenomics – A Precision Medicine Initiative, a landmark collaboration between GPD and NUS. This initiative builds on her earlier CYP2C19-guided “iRight4Me Antiplatelet Therapy” program, which successfully enrolled over 1,000 patients before concluding in 2024.
Her partnership with GPD has also brought her into the Malaysian precision medicine landscape. She was an invited speaker at the 1st Malaysia Pharmacogenomics Summit (hosted by the Precision Medicine and Scientific Wellness Association) and has contributed to Ministry of Health Malaysia sessions and workshops on PGx adoption.
Within the National University Health System, she sits on the Pharmacogenomics Steering Committee, leading education and training integration into pharmacy curricula. Her broader research portfolio includes statin pharmacogenomics, digital health interventions for post-myocardial infarction care, and AI-assisted medication adherence programs.
Professional Qualifications
- Associate Professor, Clinical & Pharmacy Practice, Department of Pharmacy, National University of Singapore
- PTPS, Policy, Research and Evaluation Department (PRED), Ministry of Health (Singapore)
- Board Member, Pharmacy Specialist Accreditation Board and Chair, Pharmacy Specialist Accreditation Committee (Cardiology)
- Assistant Residency Director, R2 Cardiology Residency Pharmacy Residency Program, Ministry of Health (Singapore)
- Lead, National Metrics Drug-Related Problems and Productivity committee, Chief Pharmacist Office, Ministry of Health (Singapore)
- Board Member and Co Treasurer, International Society of Cardiovascular Pharmacotherapy
- 2012 Doctor of Pharmacy (Pharm.D.), National University of Singapore
- 1997 Bachelor of Science (Pharmacy), National University of Singapore
- 2018 National Collaborative Prescribing Program Graduate, Ministry of Health & National University of Singapore
- 2012 Singapore Pharmacy Board Specialist Register for Cardiology Specialist Pharmacist
- Board Certified Pharmacotherapy Specialist from 2004, recertified in 2011
- Board Certified Pharmacotherapy Specialist Added Qualification in Cardiology from 2009
- Certified Geriatric Pharmacist from 2005
- Collaborative Institutional Training Initiative (CITI) certification on research ethics course
Publications
Cheng Keat Tan, David Bin-Chia Wu, Seh Yi Joseph Tan, Syed Saqib Imran, Xue Ting Wee, Doreen Su-Yin Tan. Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel. European Cardiology Review 2023;18:e60.
Wee J, Tan XR, Gunther SH, Ihsan M, Leow MKS, Tan DS, Eriksson JG, Lee JKW. Effects of medications on heat loss capacity in chronic disease patients: health implications amidst global warming. Pharmacol Rev. 2023 Jun 16:PHARMREV-AR-2022-000782. doi: 10.1124/pharmrev.122.000782. Epub ahead of print. PMID: 37328294.
Tang SWY, Mai AS, Chew NWS, Tam WWS, Tan DS. The clinical impact of anti-hypertensive treatment drug-gene pairs in the asian population: a systematic review of publications in the past decade. J Hum Hypertens. 2023 Mar;37(3):170-180. doi: 10.1038/s41371-022-00765-y. Epub 2022 Oct 27. PMID: 36302845.
Soh XQ, Tan DS, Chan ECY. Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Cardiovasc Drugs Ther. 2022 May 14. doi: 10.1007/s10557-022-07346-8. Epub ahead of print. PMID: 35567727.
Tan, H. X., et al. (2022). “Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea.” Healthc Inform Res 28(2): 112-122.
Tan JWC, Chew DP, Tsui KL, Tan D, Duplyakov D, Hammoudeh A, Zhang B, Li Y, Xu K, Ong PJ, Firman D, Gamra H, Almahmeed W, Dalal J, Tam LW, Steg G, Nguyen QN, Ako J, Al Suwaidi J, Chan M, Sobhy M, Shehab A, Buddhari W, Wang Z, Fong AYY, Karadag B, Kim BK, Baber U, Chin CT, Han YL. 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. Eur Cardiol. 2021 Nov 8;16:e43. doi: 10.15420/ecr.2021.35. PMID: 34815751; PMCID: PMC8591619.
Ng TM, Hing WC, Koh TY, Chang WT, Chang GSW, Heng JW, Abuaman IB, Sia BY, Saw YC, Chan D, Tan CH, Fan WS, Franky F, Tan PC, Tan CWY, Sng JHL, Yap CW, Gnanamani SUD, Tan DSY. Merits of a harmonised system to classify drug-related problems in Singapore. Ann Acad Med Singap. 2021 Jul;50(7):572-577. doi: 10.47102/annals-acadmedsg.202176. PMID: 34342338.
Kim JH, Tan DS, Chan MYY. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. Pharmacogenomics J. 2021 Apr;21(2):243-250. doi: 10.1038/s41397-020-00204-6. Epub 2021 Jan 18. PMID: 33462345.
Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int J Cardiol. 2021 May 15:S0167-5273(21)00824-X. doi: 10.1016/j.ijcard.2021.05.012. Epub ahead of print. PMID: 34000356.
Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol. 2021 Mar 2;16:e02. doi: 10.15420/ecr.2020.40. PMID: 33708263; PMCID: PMC7941380.
Narasimhalu K, Ang YK, Tan DSY, De Silva DA, Tan KB. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. Clin Drug Investig. 2020 Nov;40(11):1063-1070. doi: 10.1007/s40261-020-00970-y. PMID: 32959334.
Chang GS, Tan DS. Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds. Eur Cardiol. 2020 Jun 29;15:e53. doi: 10.15420/ecr.2019.12. PMID: 32684983; PMCID: PMC7362335.
Png WY, Wong XY, Kwan YH, Lin YY, Tan DS. Perspective on CYP2C19 genotyping test among patients with acute coronary syndrome – a qualitative study. Future Cardiol. 2020 Jun 11. doi: 10.2217/fca-2020-0036. Epub ahead of print. PMID: 32524842.
Wee JW, Png WY, Wong XY, Kwan YH, Lin YY, Tan DS, Wee HL, Measuring preferences for CYP2C19 genotyping in patients with acute coronary syndrome – a discrete choice experiment. Future Cardiol, 2020.
Patients’ and Caregivers’ Attitudes Towards Deprescribing in Singapore. J Gerontol A Biol Sci Med Sci, 2020. Kua, C.H., E. Reeves, Tan DSY et al on behalf of Pharmaceutical Society of Singapore’s Deprescribing Workgroup.
Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction – A Time Dependent Analysis Study. Koh L, Kim JH, Tan DS, Leong WQ, Syed SI, Leow KL and Wee EW. Acta Cardiol Sin 2020;36:8E15.
CYP2C19 phenotype in South‐East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events. Tan DS, Aw JWX, Winther M, Goh LL, Ong HY, Wee E, Liu J, Ho HK. J Clin Pharm Ther. 2019 Oct 31. doi: 10.1111/jcpt.13062. [Epub ahead of print]. https://doi.org/10.1111/jcpt.13062
Sex Differences in 1-Year Rehospitalisation for Heart Failure and Myocardial Infarction after Primary Percutaneous Coronary Intervention. Zheng HL, Foo LL, Tan HC, et al. Am J Cardiology 2019; 123(12). DOI: 10.1016/j.amjcard.2019.03.021.
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP. Eur Heart J. 2018 Dec 22. doi: 10.1093/eurheartj/ehy802. [Epub ahead of print]
Expert Opinion. Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians? Tan DSY. Eur Cardiology Review 2018.
Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR. Ng HOT, Goh JJN, Aw JWX, Lin YY, Fong AYY, Tiong LL, Tan D. Journal of Thrombosis and Thrombolysis 2018.
Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. Wang KL, Chiu CC, Guigliano R, Tan D, Lin CY, Lai EY, Goto S, Chiang CE. Journal of Stroke and Cerebrovascular Diseases 2017; 27(4). DOI: 10.1016/j.strokecerebrovasdis.2017.10.027
Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore. Wee XT, Ho LM, Ho HK, Lee JYC, Yap CW, William H, Chan LCE, Tay HC, Goh CEM, Tan D. Clinical Cardiology 2017.
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Lin L, Wu DBC, Abdul Aziz MI, Wong R, Sim D, Leong G, Yong QW, Tan D, Kwong N. Journal of Medical Economics 2017, published first online
Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Wang KL, Chiu CC, Tan D, Lin CY, Lai EY, Goto S, Giugliano RP, Chiang CE. Journal of the Formosan Medical Association 2017; 116:591-8
Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm. Dorajoo SR, See V, Chan CT, Tan JZ, Tan DS, Abdul Razak SM, Ong TT, Koomanan N, Yap CW, Chan A . Pharmacotherapy. 2017 Mar;37(3):268-277
Association between total daily doses with duration of hospitalization among readmitted patients in a multi ethnic asian population. Teo V, Toh MR, Kwan YH, Raaj S, Tan DSY, Tan JZY. Saudi Pharmaceutical Journal 2015
Association between number of doses per day, number of medications and patient’s non-compliance, and frequency of readmissions in a multi-ethnic Asian population. Ming Ren Toh, Vivien Teo, Yu Heng Kwan, Sreemanee Raaj, Doreen Su-Yin Tan, Joyce Zhen Yin Tan. Preventive Medicine Reports 1 (2014) 43–47.
Asian Study of CLOPidogrel Pharmacogenetics (ASCLOP), Int J Cardiol 2014 Feb 1;171(2):e21-3. doi: 10.1016/j.ijcard.2013.11.126. Epub 2013 Dec 12. PubMed PMID: 24377711. Tan DS, Yeo AH, Ho HK, Wee HL, Ong HY Tan DS, Yeo AH, Ho HK, Wee HL, Ong HY.